• Channels
    • All News
    • Premium Content
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

In a fresh blow, Bio­gen los­es a big court fight with My­lan over its block­buster Tec­fidera patent

3 years ago
Pharma

As Bio­Marin’s lead ri­val wanes, Pfiz­er and Sang­amo post a promis­ing up­date for he­mo­phil­ia A gene ther­a­py

3 years ago
R&D
Cell/Gene Tx

Covid-19 roundup: Roche's Actem­ra marred by neg­a­tive re­sults; Here comes an­oth­er sin­gle-armed remde­sivir tri­al

3 years ago
Coronavirus

Chi­nese vac­cine de­vel­op­ers have be­gun to shed some se­cre­cy around Covid-19 can­di­dates. What do we know?

3 years ago
China
Coronavirus

Bio­Marin spells out a trou­bling slide in Fac­tor VI­II lev­els for its big block­buster con­tender val­rox

3 years ago
R&D
Cell/Gene Tx

Mer­ck eats the lunch Bris­tol My­ers nev­er served, win­ning TMB-based OK for Keytru­da

3 years ago
Pharma

A Bay Area up­start with leg­endary god­fa­thers breaks cov­er, tout­ing claims of a cu­ra­tive tech, uni­corn sta­tus and a $300M plan to shoot for an ap­proval

3 years ago
Financing
Startups

Adding bil­lions in val­ue, Eli Lil­ly suc­ceeds where Pfiz­er failed, halt­ing breast can­cer re­cur­rence

3 years ago
R&D

Take­da spins out a pipeline of ‘in­ter­est­ing but still dif­fi­cult’ psych drugs in $2B deal as it wraps up a post-merg­er R&D shake­out

3 years ago
Deals
R&D

Bil­lions on the ta­ble, GSK’s Hal Bar­ron antes $120M cash to part­ner with a spe­cial­ist in syn­thet­ic lethal­i­ty

3 years ago
Deals

Eye­ing a hot IPO mar­ket, 4DMT tops up its cash re­serves and preps a leap in­to the clin­ic with be­spoke gene ther­a­py vec­tors

3 years ago
Financing
Cell/Gene Tx

On a hir­ing spree, Mod­er­na re­cruits an­oth­er Am­gen vet for the ex­ec­u­tive com­mit­tee; Re­pare, For­ma set terms for IPO

3 years ago
News Briefing

Mo­men­ta clears a PhII hur­dle on nipo — but one big ri­val re­mains well in the lead in this packed field

3 years ago
R&D

Sure, Bit Bio got some sig­nif­i­cant cash for its cell cod­ing work. But it’s the in­sid­ers who are back­ing them that will gar­ner the at­ten­tion

3 years ago
Financing
R&D

Sino­vac posts pos­i­tive PhI/II da­ta for their Covid-19 vac­cine as re­searchers rush in­to a piv­otal test

3 years ago
R&D
Coronavirus

Mod­er­na bur­nish­es its PhI­II-ready Covid-19 vac­cine with promis­ing mouse da­ta — which sug­gest one dose might be enough af­ter all

3 years ago
R&D
Coronavirus

Ver­tex and CRISPR spot­light an­oth­er im­por­tant gene edit­ing ad­vance in a march to a hoped-for cure

3 years ago
R&D
Cell/Gene Tx

It's all about the heart: Di­a­betes ma­jor No­vo Nordisk bets $725M up­front to buy car­dio-fo­cused As­traZeneca spin­off

3 years ago
Deals
R&D

Mod­er­na floors it in­to PhI­II with their Covid-19 vac­cine, plan­ning quick start with a thumbs-up from FDA on tri­al de­sign, dosage

3 years ago
R&D
Coronavirus

Covid-19 roundup: Re­gen­eron puts its an­ti­bod­ies in­to the clin­ic, rac­ing with Eli Lil­ly for fall au­tho­riza­tion

3 years ago
Coronavirus

'Tremen­dous' an­i­mal da­ta in­spire GV, ARCH's $63M boost­er for Sekar Kathire­san's dri­ve to rel­e­gate coro­nary heart dis­ease to his­to­ry

3 years ago
Financing

Sanofi sharp­ens fo­cus on bis­pecifics, and Chi­na, with Al­pham­ab deal

3 years ago
Deals
China

Fu­ji­film dou­bles down on ex-Bio­gen fa­cil­i­ty with $928M in­fu­sion as biotech boom fu­els CD­MO growth

3 years ago
Outsourcing

An­a­lysts cheer as Ab­b­Vie pays $750M cash to al­ly it­self with Gen­mab on a pipeline of can­cer drugs, with bil­lions more on the ta­ble

3 years ago
Deals
First page Previous page 157158159160161162163 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Premium Content
  • Don't Miss
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints Company 2023

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
Endpoints News

Log in to your account

e-mail

password

Endpoints News

request magic link

If you're already an Endpoints subscriber, enter your email below for a magic link that lets you log in quickly without using a password. Please note the magic link is one-time use only and expires after 24 hours.

email

Endpoints News

reset password

We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours.

email

Endpoints News

About You

Subscriptions

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 2 PM ET

ENDPOINTS MARKETING RX Tue at 2 PM ET

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET